Biologics

Generex Biotechnology Corp. signed a letter to purchase Medisource Partners, an FDA-registered distributor.

SpinalCyte received a new Australian patent related to its fibroblast technology.

DiscGenics' injectable disc cell therapy, IDCT, passed the initial safety review of its first-in-human trial for moderate degenerative disc disease treatment.

JRF Ortho provides allograft joint repair solutions.

The FDA granted StemCyte permission to proceed with its phase 2 investigational new drug application for the Allogenic Human Leukocyte Antigen-Matched Umbilical Cord Blood Mononuclear Stem Cells (MC001).

Carmell Therapeutics, a developer of plasma-based bioactive materials to accelerate bone and soft tissue healing, welcomed Wendy DiCicco to its board of directors.

The Department of Defense granted a team of researchers at the University of Arizona in Tucson $2 million to study bone regrowth technology, according to The Brunswick News.

Michael B. Gerhardt, MD, is a sports medicine specialist and orthopedic surgeon at Cedars-Sinai Kerlan-Jobe Institute in Los Angeles and team physician for the LA Galaxy and U.S. Soccer Men's National Team.

Here are 10 must-read Q&As from 2018 on biologics.

Robert LaPrade, MD, is an orthopedic surgeon based in Colorado.